Metamark Obtains Draft Medicare Coverage for ProMark

CAMBRIDGE, Mass., May 18, 2016 /PRNewswire/ -- Metamark Genetics, Inc., ("Metamark" or the "Company"), a leader in providing critical diagnostic and prognostic information to enable more informed treatment decisions for urological cancer, today announced that Palmetto GBA, Noridian Healthcare Solutions, LLC, and CGS Administrators, LLC, three Medicare Administrative Contractors (MACs) that assess novel molecular diagnostic technologies, have issued draft local coverage determinations (LCDs) for ProMark, the first and only proteomic prognostic test for early-stage prostate cancer. The draft LCDs are posted to the Medicare Coverage Database on the Centers for Medicare & Medicaid Services (CMS) website, and propose to establish reimbursement coverage for eligible prostate cancer patients to help determine which patients can be conservatively managed rather than treated with definitive surgery or radiation therapy.

"These draft LCDs represent another significant milestone for ProMark, moving Metamark closer to our goal of ensuring that all prostate cancer patients have greater access to additional, critical information about their disease aggressiveness so they can make an appropriate and personalized treatment decision," said Jerry Williamson, President and CEO. "The draft LCDs closely follow ProMark's inclusion in the 2016 National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines¹ in March, further demonstrating the growing adoption of ProMark as a meaningful prognostic tool in the care of patients with clinically localized prostate cancer."

ProMark predicts cancer aggressiveness in patients with biopsy Gleason Scores of 3+3 and 3+4, providing a fully independent and individualized prediction that the cancer can be managed without aggressive treatment, or an indication that therapy may be appropriate.

¹ NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Prostate Cancer (Version 2.2016). http://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf. Accessed March 2016.

About ProMark®
Launched in late 2014, ProMark® is the first proteomic classifier of biopsied prostate tissue to assess whether an early-stage prostate tumor is aggressive or indolent. Test results generated in Metamark's Cambridge, Mass. CLIA-certified laboratory can aid the decision whether to treat the cancer aggressively or to choose a course of active surveillance.

About Metamark®
Metamark Genetics, Inc. is a privately-held biotechnology company founded to develop novel, function-based prognostic and diagnostic tests aimed at improving cancer care. The company's proprietary genomic and proteomic discovery platforms have led to significant discoveries in several disease areas, including prostate, bladder, colon, and breast cancers. Through the acquisition of HealthTronics Laboratory Solutions in 2013, Metamark has become a leading provider of specialty urological pathology testing services with the first fully integrated clinical model for the prostate cancer care pathway.

For more information, please visit the company's website: www.metamarkgenetics.com.

Metamark® and ProMark® are registered trademarks of Metamark Genetics, Inc.

Logo - http://photos.prnewswire.com/prnh/20160310/342770LOGO

SOURCE Metamark Genetics, Inc.

Related Links

http://www.metamarkgenetics.com